Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30950193 | 1.00 | LMNA (0.62) | LMNARECQLCHRNA7ALDH1A1KMT2A | |
| SCHEMBL2198159 | 0.84 | CHRNA7 (0.49) | LMNARECQLCHRNA7ALDH1A1KMT2A | |
| SCHEMBL27185443 | 0.83 | KMT2A (0.60) | LMNARECQLCHRNA7ALDH1A1KMT2A | |
| SCHEMBL1896215 | 0.82 | LMNA (0.66) | LMNARECQLALDH1A1KMT2AMAOB | |
| SCHEMBL20604721 | 0.82 | LMNA (0.50) | LMNARECQLCHRNA7ALDH1A1KMT2A | |
| SCHEMBL930916 | 0.82 | CHRNA7 (0.45) | LMNARECQLCHRNA7ALDH1A1KMT2A | |
| SCHEMBL10648590 | 0.81 | LMNA (0.64) | LMNARECQLALDH1A1KMT2AMAOB | |
| SCHEMBL1287575 | 0.79 | LMNA (0.62) | LMNARECQLALDH1A1KMT2AMAOB | |
| SCHEMBL16795696 | 0.79 | LMNA (0.62) | LMNARECQLCHRNA7ALDH1A1KMT2A | |
| SCHEMBL931020 | 0.79 | MAOB (0.51) | LMNARECQLCHRNA7ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023066357-A1 | FUSED CYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-04-27 | — | — | WO | disclosed |
| EP-3653613-B1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | BEBETTER MED INC (CN) | 2022-11-16 | — | — | EP | disclosed |
| US-11306102-B2 | 1,3-di-substituted ketene compound and application thereof | BEBETTER MED INC. (CN) | 2022-04-19 | — | — | US | disclosed |
| US-20210122761-A1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | BEBETTER MED INC. (CN) | 2021-04-29 | — | — | US | disclosed |
| EP-3653613-A1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | Guangzhou Bebetter Medicine Technology Co., Ltd. (CN) | 2020-05-20 | — | — | EP | disclosed |
| WO-2015087094-A1 | NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-06-18 | — | — | WO | disclosed |
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1373240-B1 | RETINOID X RECEPTOR MODULATORS | LILLY CO ELI (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040167160-A1 | Retinoid x receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| EP-1373240-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002071827-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167160-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | LMNA 2800/4885RECQL 577/4885CHRNA7 686/4885 |
| US-20210122761-A1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | PPARA, FABP1, PPARG | LMNA 2054/4885RECQL 4839/4885CHRNA7 1661/4885 |
| US-20080090860-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | LMNA 2550/4885RECQL 700/4885CHRNA7 761/4885 |
| US-11306102-B2 | 1,3-di-substituted ketene compound and application thereof | PPARA, FABP1, PPARG | LMNA 2054/4885RECQL 4839/4885CHRNA7 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.